Feasibility Study: The Effect of Prazosin for Nighttime Symptoms of Civilian PTSD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00174551
Recruitment Status : Unknown
Verified September 2005 by Rainier Associates.
Recruitment status was:  Active, not recruiting
First Posted : September 15, 2005
Last Update Posted : September 11, 2006
Information provided by:
Rainier Associates

Brief Summary:
Investigating the effect of prazosin for nighttime symptoms of civilian Posttraumatic Stress Disorder.

Condition or disease Intervention/treatment Phase
Stress Disorders, Post-Traumatic Drug: prazosin Not Applicable

Detailed Description:
Each subject will receive prazosin and placebo trials, the order randomized. Day and nighttime symptoms will be monitored.

Study Type : Interventional  (Clinical Trial)
Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: The Effect of Prazosin for Nighttime Symptoms of Civilian PTSD
Study Start Date : November 2003
Study Completion Date : November 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Sleep time
  2. REM sleep time
  3. Nightmare frequency
  4. CGI

Secondary Outcome Measures :
  1. Distressed Awakenings frequency
  2. PCL-C

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • must meet DSM-IV criterion for PTSD

Exclusion Criteria:

  • Must not have untreated sleep apnea

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00174551

United States, Washington
Fletcher B. Taylor
Tacoma, Washington, United States, 98467
Sponsors and Collaborators
Rainier Associates
Principal Investigator: Fletcher B Taylor, M.D. Rainier Associates Identifier: NCT00174551     History of Changes
Other Study ID Numbers: 20031050
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: September 11, 2006
Last Verified: September 2005

Additional relevant MeSH terms:
Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic
Trauma and Stressor Related Disorders
Mental Disorders
Antihypertensive Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs